My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Clene Inc. - Common Stock (NQ:CLNN)

6.120 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Clene Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Why Clene Shares Are Nosediving
Clene Inc. (NASDAQ: CLNN) shares are trading lower by 13.81% to $0.90 Friday morning after the company announced pricing of a $40 million public offering. 
Via Benzinga
Where Clene Stands With Analysts
 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
Why Clene Shares Are Trading Lower By 20%; Here Are 20 Stocks Moving Premarket
Gainers Evelo Biosciences, Inc. (NASDAQ: EVLO) shares gained 192.8% to $0.2427 in pre-market trading. Evelo Biosciences was granted U.S. patent #11672834 for "Prebiotic Compositions And Methods Of Use... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
Expert Ratings for Clene
 
Via Benzinga
Clene: Q1 Earnings Insights
 
Via Benzinga
Analyst Expectations for Clene's Future
 
Via Benzinga
Analyst Ratings for Clene
 
Via Benzinga
Clene's Return On Capital Employed Overview
 
Via Benzinga
Gilead Sciences To Rally Around 28%? Here Are 10 Other Analyst Forecasts For Tuesday
Morgan Stanley raised the price target for DraftKings Inc. (NASDAQ: DKNG) from $23 to $25. Morgan Stanley analyst Stephen Grambling maintained an Overweight rating. DraftKings shares fell 0.2% to close... 
Via Benzinga
Valero Energy To Rally 32%? Here Are 10 Other Analyst Forecasts For Monday
Credit Suisse boosted the price target for The Boeing Company (NYSE: BA) from $200 to $220. Credit Suisse analyst Scott Deuschle maintained a Neutral rating on the stock. Boeing shares fell 0.4% to... 
Via Benzinga
The Latest Analyst Ratings for Clene
 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
It's time for another breakdown of the biggest pre-market stock movers traders will want to know about on Thursday morning! 
Via InvestorPlace
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 8, 2023
 
Via Benzinga
Clene's Lead Amyotrophic Lateral Sclerosis Shows Improved Function, Slowed Disease Progression
 
Via Benzinga
Clene: Still in the Running for ALS
New York, New York, United States - 02-14-2023 (PR Distribution™) - 
Via PR Distribution
Topics Death
Why Frequency Therapeutics Are Trading Lower By 82%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Vallon Pharmaceuticals, Inc. (NASDAQ: VLON) shares jumped 120.5% to $1.02 after jumping over 72% on Friday. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Clene Shares Move Higher On Encouraging Data From Multiple Sclerosis Candidate
 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Clene Reports New Data from the VISIONARY-MS Phase 2 Study in Multiple Sclerosis Demonstrating CNM-Au8® Treatment Improved Brain Neuronal Structural Integrity
From Clene Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
Clene Nanomedicine Announces Participation in Renmark Virtual Non-Deal Roadshow Series on January 18 and January 23
From Clene Inc.
Via GlobeNewswire
Clene's COVID-19 Candidate Shows No Substantial Symptom Resolution In Phase 2 Trial
 
Via Benzinga
Clene Nanomedicine Reports Topline Results of Phase 2 COVID-19 Study of CNM-ZnAg
From Clene Inc.
Via GlobeNewswire
Clene Announces Closing of $5 Million Debt Facility from the State of Maryland
Funding Demonstrates Importance of Working with Private Sector to Improve Lives of Marylanders, says Governor Hogan 
From Clene Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
VISIONARY-MS Trial Results Featured in Platform Presentation at PACTRIMS 2022: CNM-Au8® Demonstrated Global Neurological Improvement in Stable MS Patients as Adjunct to Background Disease Modifying Therapies
From Clene Inc.
Via GlobeNewswire
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.